{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:20:47Z","timestamp":1761920447060,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Biogen Idec, Novartis Pharmaceuticals, TEVA, Sanofi-Genzyme and Roche"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.msard.2018.05.014","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T02:42:37Z","timestamp":1526611357000},"page":"38-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8889-603X","authenticated-orcid":false,"given":"L.J.W.","family":"Canham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Manara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Fawcett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rolinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mortimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.E.A.","family":"Inglis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.A.","family":"Cottrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2018.05.014_bib0001","unstructured":"Group AoBNMA. Guidance on the prevention of Listeria infection after alemtuzumab treatment of multiple sclerosis. 2017."},{"issue":"10","key":"10.1016\/j.msard.2018.05.014_bib0005","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1086\/508462","article-title":"Community-acquired Listeria monocytogenes meningitis in adults","volume":"43","author":"Brouwer","year":"2006","journal-title":"Clin. Infect. Dis"},{"issue":"17","key":"10.1016\/j.msard.2018.05.014_bib0006","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.msard.2018.05.014_bib0004","first-page":"123","article-title":"Listeria rhombencephalitis mimicking a demyelinating event in an immunocompetent young patient","volume":"23","author":"Decard","year":"2017"},{"issue":"2","key":"10.1016\/j.msard.2018.05.014_bib0002","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4161\/viru.19586","article-title":"Targeting of the central nervous system by Listeria monocytogenes","volume":"3","author":"Disson","year":"2012","journal-title":"Virulence"},{"issue":"1","key":"10.1016\/j.msard.2018.05.014_bib0003","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12883-017-0848-8","article-title":"Listeria monocytogenes infection associated with alemtuzumab\u2014a case for better preventive strategies","volume":"17","author":"Holmoy","year":"2017","journal-title":"BMC Neurol."},{"article-title":"National Institute for Health and Care Excellence: Clinical Guidelines","year":"2014","series-title":"Multiple Sclerosis: Management of Multiple Sclerosis in Primary and Secondary Care","key":"10.1016\/j.msard.2018.05.014_bib0010"},{"key":"10.1016\/j.msard.2018.05.014_bib0008","series-title":"31st Congress of the European Commitee for Treatment and Research in Multiple Sclerosis (ECTRIMS)","article-title":"Alemtuzumab related Listeria infections\u2014a growing concern?","author":"Ohm S","year":"2015"},{"issue":"11 Supplement 1","key":"10.1016\/j.msard.2018.05.014_bib0009","first-page":"582","article-title":"Alemtuzumab related Listeria infections\u2014a growing concern?","volume":"23","author":"Ohm S","year":"2015","journal-title":"Mult. Scler. J."},{"issue":"2 Suppl 5","key":"10.1016\/j.msard.2018.05.014_bib0013","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1053\/j.seminoncol.2006.01.027","article-title":"Strategies in the management of alemtuzumab-related side effects","volume":"33","author":"Osterborg","year":"2006","journal-title":"Semin. Oncol."},{"issue":"1","key":"10.1016\/j.msard.2018.05.014_bib0011","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0378-1135(97)00132-6","article-title":"Prolonged persistence of Listeria monocytogenes after intragastric infection in corticosteroid-treated mice","volume":"58","author":"Prats","year":"1997","journal-title":"Vet. Microbiol."},{"issue":"7","key":"10.1016\/j.msard.2018.05.014_bib0007","doi-asserted-by":"crossref","first-page":"14669","DOI":"10.3390\/ijms160714669","article-title":"Listeria meningitis complicating alemtuzumab treatment in multiple sclerosis\u2013report of two cases","volume":"16","author":"Rau","year":"2015","journal-title":"Int. J. Mol. Sci"},{"issue":"3","key":"10.1016\/j.msard.2018.05.014_bib0012","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1212\/NXI.0000000000000228","article-title":"Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS","volume":"3","author":"Thomas","year":"2016","journal-title":"Neurol. (R) Neuroimmunol. Neuroinflammation"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818301743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818301743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:41:04Z","timestamp":1761900064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818301743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":13,"alternative-id":["S2211034818301743"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.05.014","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2018 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}